NCT04237649: KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

NCT04237649
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Early Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic central nervous system (CNS) metastases that require treatment
https://ClinicalTrials.gov/show/NCT04237649

Comments are closed.

Up ↑